170 related articles for article (PubMed ID: 29673751)
1. [Primary cutaneous CD30+ T-cell lymphoproliferation during treatment with fingolimod: Case report and literature review].
Cesbron E; Monfort JB; Giannesini C; Duriez P; Moguelet P; Senet P; Francès C; Barbaud A; Chasset F
Ann Dermatol Venereol; 2018; 145(6-7):433-438. PubMed ID: 29673751
[TBL] [Abstract][Full Text] [Related]
2. Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
Papathemeli D; Gräfe R; Hildebrandt U; Zettl UK; Ulrich J
Mult Scler; 2016 Dec; 22(14):1888-1890. PubMed ID: 27207455
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous CD30
Connolly A; Grandi V; Stefanato CM; Palmer R; Weir A; Whittaker S
Br J Dermatol; 2018 Dec; 179(6):1400-1401. PubMed ID: 30007065
[No Abstract] [Full Text] [Related]
4. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
Samaraweera AP; Cohen SN; Akay EM; Evangelou N
Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.
Manouchehri N; Mirmosayyeb O; Badihian S; Shaygannejad V
Mult Scler Relat Disord; 2018 Jan; 19():121-123. PubMed ID: 29195114
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the t(2;5) (p23;q35) translocation in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
Wood GS
Leuk Lymphoma; 1998 Mar; 29(1-2):93-101. PubMed ID: 9638979
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
Ferreira CR; Zhao S; Sanches JA; Miyashiro D; Cury-Martins J; Azevedo RS; Zerbini MCN; Natkunam Y; Gratzinger D
Diagn Pathol; 2019 Oct; 14(1):115. PubMed ID: 31640798
[TBL] [Abstract][Full Text] [Related]
8. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
[TBL] [Abstract][Full Text] [Related]
9. Nodal Involvement by CD30
Lezama LS; Gratzinger D
Arch Pathol Lab Med; 2018 Jan; 142(1):139-142. PubMed ID: 29257929
[TBL] [Abstract][Full Text] [Related]
10. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
[TBL] [Abstract][Full Text] [Related]
11. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases.
Vergier B; Beylot-Barry M; Pulford K; Michel P; Bosq J; de Muret A; Beylot C; Delaunay MM; Avril MF; Dalac S; Bodemer C; Joly P; Groppi A; de Mascarel A; Bagot M; Mason DY; Wechsler J; Merlio JP
Am J Surg Pathol; 1998 Oct; 22(10):1192-202. PubMed ID: 9777981
[TBL] [Abstract][Full Text] [Related]
12. Characterization of primary cutaneous CD8+/CD30+ lymphoproliferative disorders.
Martires KJ; Ra S; Abdulla F; Cassarino DS
Am J Dermatopathol; 2015 Nov; 37(11):822-33. PubMed ID: 26485239
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder.
Mallet V; Bruneau J; Zuber J; Alanio C; Leclerc-Mercier S; Roque-Afonso AM; Kraft ARM; Couronné L; Roulot D; Wedemeyer H; Albert ML; Hillon P; Laroche L; Pol S; Hermine O
J Hepatol; 2017 Dec; 67(6):1334-1339. PubMed ID: 28860025
[TBL] [Abstract][Full Text] [Related]
14. A Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder Arising in a Patient With Multiple Myeloma and Cutaneous Amyloidosis.
Romano RC; Cohen DN; Howard MT; Wieland CN
Am J Dermatopathol; 2016 May; 38(5):388-92. PubMed ID: 26981738
[TBL] [Abstract][Full Text] [Related]
15. CD30+ T-cell lymphoproliferative disorders.
Martin JM; Wu H; Barta SK
Chin Clin Oncol; 2019 Feb; 8(1):4. PubMed ID: 30525751
[TBL] [Abstract][Full Text] [Related]
16. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
17. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.
Kummer JA; Vermeer MH; Dukers D; Meijer CJ; Willemze R
J Invest Dermatol; 1997 Nov; 109(5):636-40. PubMed ID: 9347791
[TBL] [Abstract][Full Text] [Related]
18. Benign atypical intravascular CD30+ T-cell proliferation: a recently described reactive lymphoproliferative process and simulator of intravascular lymphoma: report of a case associated with lichen sclerosus and review of the literature.
Kempf W; Keller K; John H; Dommann-Scherrer C
Am J Clin Pathol; 2014 Nov; 142(5):694-9. PubMed ID: 25319987
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment.
Willemze R; Beljaards RC
J Am Acad Dermatol; 1993 Jun; 28(6):973-80. PubMed ID: 8388410
[TBL] [Abstract][Full Text] [Related]
20. CD30-positive T-cell lymphoproliferative disorder of the oral mucosa--an indolent lesion: report of 4 cases.
Agarwal M; Shenjere P; Blewitt RW; Hall G; Sloan P; Pigadas N; Banerjee SS
Int J Surg Pathol; 2008 Jul; 16(3):286-90. PubMed ID: 18387994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
